



CARDIOVASCULAR NEWS

Niacin tablets help prevent coronary heart disease

Data presented in conjunction with the Canadian Cardiovascular Congress shows therapy with prescription, extended-release niacin tablets significantly increases high-density lipoprotein cholesterol (HDL-C), high levels of which are important for preventing coronary heart disease (CHD).

Results from long-term clinical outcome trials showed niacin, in combination therapy with other lipid-lowering drugs, slowed progression and promoted regression of coronary atherosclerosis and decreased cardiovascular morbidity and mortality.

“This increase in HDL-C is significant, given that epidemiologic data suggests that for every 1%

increase in HDL-C levels there is a 2% to 3% reduction in the risk of a coronary event,” says Dr. Jiri Frohlich, director of Lipid Clinic, St. Paul’s Hospital, Vancouver, British Columbia.

Prescription, extended-release niacin tablets are administered in a convenient once-daily, nighttime dose and significantly reduce the flushing associated with the over-the-counter, immediate-release (IR) formulations and are as effective as the IR formulations.

Increasing HDL can cut coronary event risk. Calgary (Alberta). November 15, 2004.

InterCure’s RESPeRATE® proven to lower blood pressure

Millions of Canadians with high blood pressure can now benefit from the first non-drug medical device clinically proven to reduce high blood pressure without side-effects.

InterCure, Inc.’s RESPeRATE® device, already used by thousands of patients and doctors in the U.S., is based on the established scientific evidence that certain breathing exercises with prolonged exhalation can lower blood pressure.

The therapeutic powers of RESPeRATE have been validated by seven separate clinical trials, which

repeatedly found within a few weeks of using the device for as little as 15 minutes, three to four times a day, there resulted a significant and sustained reduction in blood pressure. This reduction was in addition to other treatments, such as medication, diet and exercise.

RESPeRATE is now available in Canada by calling ManthaMed at 1-800-728-7327 or can be obtained online at www.resperate.ca.

Health Canada approved InterCure’s breakthrough therapeutic breathing device to lower blood pressure. Fort Lee (New Jersey). October 25, 2004.